PICIOTTI, ROBERTO
PICIOTTI, ROBERTO
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease
2023 R.M. Pipitone, F. Malvestiti, G. Pennisi, O. Jamialahmadi, P. Dongiovanni, G. Bertolazzi, J. Pihlajamäki, H. Yki-Järvinen, U. Vespasiani-Gentilucci, F. Tavaglione, S. Maurotti, C. Bianco, G. Di Maria, M. Enea, A.L. Fracanzani, V. Kärjä, G. Lupo, V. Männistö, M. Meroni, R. Piciotti, S. Qadri, R. Zito, A. Craxì, V. Di Marco, C. Cammà, C. Tripodo, L. Valenti, S. Romeo, S. Petta, S. Grimaudo
{PD}-1/{PD}-L1 Immuno-Mediated Therapy in {NAFLD}: Advantages and Obstacles in the Treatment of Advanced Disease
2022 R. Lombardi, R. Piciotti, P. Dongiovanni, M. Meroni, S.R. Fargion, A.L. Fracanzani
TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
2022 M. Longo, M. Meroni, E. Paolini, V. Erconi, F. Carli, F.R. Fortunato, D. Ronchi, R. Piciotti, S. Sabatini, C. Macchi, A. Alisi, L. Miele, G. Soardo, G.P. Comi, L.V.C. Valenti, M. Ruscica, A.L. Fracanzani, A. Gastaldelli, P. Dongiovanni
MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients
2022 M. Meroni, M. Longo, E. Paolini, R. Lombardi, R. Piciotti, P. Francione, S. Badiali, M. Maggioni, A.L. Fracanzani, P. Dongiovanni
Recreating gut-liver axis during NAFLD onset by using a Caco-2/HepG2 co-culture system
2022 M. Meroni, E. Paolini, M. Longo, R. Piciotti, G. Tria, S. Fargion, A. Ludovica Fracanzani, P. Dongiovanni
Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study
2021 C. Blundo, M. Giroda, N. Fusco, E. Sajjadi, K. Venetis, M.C. Leonardi, E. Vicini, L. Despini, C.F. Rossi, L. Runza, M.S. Sfondrini, R. Piciotti, E. Di Loreto, G. Scarfone, E. Guerini-Rocco, G. Viale, P. Veronesi, B. Buonomo, F.A. Peccatori, V.E. Galimberti
Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology
2021 C. Criscitiello, E. Guerini-Rocco, G. Viale, C. Fumagalli, E. Sajjadi, K. Venetis, R. Piciotti, M. Invernizzi, U. Malapelle, N. Fusco
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management
2021 K. Venetis, R. Piciotti, E. Sajjadi, M. Invernizzi, S. Morganti, C. Criscitiello, N. Fusco
Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling
2021 E. Sajjadi, K. Venetis, R. Piciotti, D. Gambini, C. Blundo, L. Runza, S. Ferrero, E. Guerini-Rocco, N. Fusco
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists
2021 N. Fusco, M. Ragazzi, E. Sajjadi, K. Venetis, R. Piciotti, S. Morganti, G. Santandrea, G.N. Fanelli, L. Despini, M. Invernizzi, B. Cerbelli, C. Scatena, C. Criscitiello
Mismatch Repair Status Characterization in Oncologic Pathology : Taking Stock of the Real-World Possibilities
2021 R. Piciotti, K. Venetis, E. Sajjadi, N. Fusco
Mismatch repair-deficient hormone receptor-positive breast cancers : Biology and pathological characterization
2021 E. Sajjadi, K. Venetis, R. Piciotti, M. Invernizzi, E. Guerini-Rocco, S. Haricharan, N. Fusco
Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in breast cancer patients
2021 M. Invernizzi, K. Venetis, E. Sajjadi, R. Piciotti, A. de Sire, N. Fusco
How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer : Between Biomarkers and Novel Cell-Based Approaches
2021 M. Ghidini, A. Petrillo, A. Botticelli, D. Trapani, A. Parisi, A. La Salvia, E. Sajjadi, R. Piciotti, N. Fusco, S. Khakoo
MICAL2 is essential for myogenic lineage commitment.
2020 N. Giarratana, F. Conti, R. La Rovere, R. Gijsbers, P. Carai, R. Duelen, T. Vervliet, G. Bultynck, F. Ronzoni, R. Piciotti, D. Costamagna, S. Fulle, I. Barravecchia, D. Angeloni, Y. Torrente, M. Sampaolesi